The characteristics of pediatric-onset inflammatory bowel disease based on our 20-year-long study

被引:0
|
作者
Tobi, Luca [1 ]
Cseh, Aron [1 ]
机构
[1] Semmelweis Egypt, Altalan Orvostudomany Kar, Gyermekgyogyaszat Klinika, MTA Kivalo Kutatohely, Budapest, Hungary
关键词
compliance; inflammatory bowel disease; pediatric; complication; surgery; QUALITY-OF-LIFE; ULCERATIVE-COLITIS; NATURAL-HISTORY; CROHNS-DISEASE; EXTRAINTESTINAL MANIFESTATIONS; MEDICATION ADHERENCE; CHILDHOOD; FEATURES; CHILDREN;
D O I
10.1556/650.2025.33249
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Among inflammatory bowel diseases (IBDs), every tenth develops during childhood, which is characterized by a more complex disease course, more extensive spread, and rapid progression. The presenting symptoms of pediatric-onset IBD are often nonspecific, and diagnostic delays increase the risk of intestinal damage, bowel resection, and growth retardation. Adolescents with IBD exhibit the lowest compliance and medication adherence rates, contributing to the frequent occurrence of complications. The most significant extraintestinal complications in pediatric-onset IBD patients include growth retardation, malnutrition, impaired bone metabolism, malignancies, and opportunistic infections. In this patient group, surgical interventions are required earlier and more frequently, and the hospitalization rate is also higher among them. Ensuring optimal disease progression and quality of life is crucial, making it essential for the physicians managing their care to be well aware of the specific characteristics of the pediatric-onset IBD patient group.
引用
收藏
页码:403 / 412
页数:10
相关论文
共 50 条
  • [41] Tofacitinib Therapy in Children and Young Adults With Pediatric-onset Medically Refractory Inflammatory Bowel Disease
    Moore, Hillary
    Dubes, Lucie
    Fusillo, Steven
    Baldassano, Robert
    Stein, Ronen
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2021, 73 (03): : E57 - E62
  • [42] Real-life experience of infliximab biosimilar in pediatric-onset inflammatory bowel disease: data from the Sicilian Network for Inflammatory Bowel Disease
    Dipasquale, Valeria
    Pellegrino, Salvatore
    Ventimiglia, Marco
    Cucinotta, Ugo
    Citrano, Michele
    Graziano, Francesco
    Cappello, Maria
    Busacca, Anita
    Orlando, Ambrogio
    Accomando, Salvatore
    Romano, Claudio
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (10) : 1007 - 1014
  • [43] Long-term Cancer Risk in Patients With Pediatric-Onset Inflammatory Bowel Diseases in the Canadian Population
    El-Matary, Wael
    Nugent, Zoann
    Bernstein, Charles N.
    Singh, Harminder
    GASTROENTEROLOGY, 2020, 159 (01) : 386 - 387
  • [44] Comment on "Long-term effectiveness and safety of anti-TNF in pediatric-onset inflammatory bowel diseases: A population-based study"
    Chaudhry, Mahrukh
    Ahmed, Abdullah
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (09)
  • [45] Characteristics of inflammatory bowel disease with onset during the first year of life
    Ruemmele, Frank M.
    El Khoury, Maurice G.
    Talbotec, Cecile
    Maurage, Chantal
    Mougenot, Jean-Francois
    Schmitz, Jacques
    Goulet, Olivier
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2006, 43 (05): : 603 - 609
  • [46] Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting
    Hemming-Harlo, Maria
    Merras-Salmio, Laura
    Nikkonen, Anne
    Kolho, Kaija-Leena
    EUROPEAN JOURNAL OF PEDIATRICS, 2024, 183 (01) : 313 - 322
  • [47] Pediatric-onset inflammatory bowel disease poses risk for low bone mineral density at early adulthood
    Guz-Mark, Anat
    Rinawi, Firas
    Egotubov, Oxana
    Shimon, Ilan
    Shamir, Raanan
    Assa, Amit
    DIGESTIVE AND LIVER DISEASE, 2017, 49 (06) : 639 - 642
  • [48] Targeted resequencing identifies defective variants of decoy receptor 3 in pediatric-onset inflammatory bowel disease
    C J Cardinale
    Z Wei
    S Panossian
    F Wang
    C E Kim
    F D Mentch
    R M Chiavacci
    K E Kachelries
    R Pandey
    S F A Grant
    R N Baldassano
    H Hakonarson
    Genes & Immunity, 2013, 14 : 447 - 452
  • [49] Drug levels of VEDOLIZUMAB in patients with pediatric-onset inflammatory bowel disease in a real-life setting
    Maria Hemming-Harlo
    Laura Merras-Salmio
    Anne Nikkonen
    Kaija-Leena Kolho
    European Journal of Pediatrics, 2024, 183 : 313 - 322
  • [50] Targeted resequencing identifies defective variants of decoy receptor 3 in pediatric-onset inflammatory bowel disease
    Cardinale, C. J.
    Wei, Z.
    Panossian, S.
    Wang, F.
    Kim, C. E.
    Mentch, F. D.
    Chiavacci, R. M.
    Kachelries, K. E.
    Pandey, R.
    Grant, S. F. A.
    Baldassano, R. N.
    Hakonarson, H.
    GENES AND IMMUNITY, 2013, 14 (07) : 447 - 452